Clinical Trial Update: Phase II Study of TAK228 in Relapsed Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase II study of TAK228 in relapsed lymphoma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• TAK-228

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-03-12